Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Arrowhead Pharmaceuticals, Inc. (ARWR)

29.5   0.1 (0.34%) 11-25 13:00
Open: 29.29 Pre. Close: 29.4
High: 29.81 Low: 29.12
Volume: 503,548 Market Cap: 3,123(M)

Technical analysis

as of: 2022-11-25 1:55:14 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 39.61     One year: 43.29
Support: Support1: 28.81    Support2: 23.97
Resistance: Resistance1: 33.91    Resistance2: 37.06
Pivot: 31.94
Moving Average: MA(5): 29.8     MA(20): 32.7
MA(100): 37.45     MA(250): 42.98
MACD: MACD(12,26): -1.2     Signal(9): -0.8
Stochastic oscillator: %K(14,3): 9     %D(3): 8.9
RSI: RSI(14): 38.8
52-week: High: 74.76  Low: 26.8
Average Vol(K): 3-Month: 834 (K)  10-Days: 785 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ARWR ] has closed above bottom band by 18.9%. Bollinger Bands are 0.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 29.98 - 30.23 30.23 - 30.39
Low: 28.59 - 28.85 28.85 - 29.03
Close: 29.05 - 29.46 29.46 - 29.74

Company Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Headline News

Fri, 25 Nov 2022
Banks' Quarterly Numbers in Focus Next Week -

Sun, 20 Nov 2022
Institutional owners may take dramatic actions as Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) recent 11% drop adds to one-year losses - Simply Wall St

Thu, 10 Nov 2022
SVB Leerink Increases Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $33.00 - MarketBeat

Wed, 09 Nov 2022
2022-11-09 | NDAQ:ARWR | Press Release | Arrowhead Pharmaceuticals Inc. - Stockhouse

Wed, 09 Nov 2022
Arrowhead sells royalty interest in olpasiran to Royalty Pharma for $250M - Seeking Alpha

Wed, 09 Nov 2022
Piper Sandler Cuts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $64.00 - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 106 (M)
Shares Float 103 (M)
% Held by Insiders 2.5 (%)
% Held by Institutions 68.1 (%)
Shares Short 3,900 (K)
Shares Short P.Month 3,870 (K)

Stock Financials

EPS -1.09
EPS Est Next Qtl -0.13
EPS Est This Year -0.42
EPS Est Next Year -0.67
Book Value (p.s.) 4.28
Profit Margin (%) -61.6
Operating Margin (%) -63.9
Return on Assets (ttm) -13.5
Return on Equity (ttm) -33.8
Qtrly Rev. Growth -29.4
Gross Profit (p.s.) 1.3
Sales Per Share 2.36
EBITDA (p.s.) -1.42
Qtrly Earnings Growth 0
Operating Cash Flow -92 (M)
Levered Free Cash Flow -66 (M)

Stock Valuations

PE Ratio -27.32
PEG Ratio -4.1
Price to Book value 6.87
Price to Sales 12.49
Price to Cash Flow -34.1

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.